Access the full text.
Sign up today, get DeepDyve free for 14 days.
G. Sauter, M. Mirlacher (2002)
Tissue microarrays for predictive molecular pathologyJournal of Clinical Pathology, 55
A. Lebeau, D. Deimling, Christine Kaltz, A. Sendelhofert, Anette Iff, Beate Luthardt, M. Untch, U. Löhrs (2001)
Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 2
P. Furtado, J. McElveen, L. Gough, K. Armour, Michael Clark, Herb Sewell, Farouk Shakib (2002)
The production and characterisation of a chimaeric human IgE antibody, recognising the major mite allergen Der p 1, and its chimaeric human IgG1 anti-idiotypeMolecular Pathology, 55
Daohai Zhang, M. Salto‐Tellez, T. Putti, E. Do, E. Koay (2003)
Reliability of Tissue Microarrays in Detecting Protein Expression and Gene Amplification in Breast CancerModern Pathology, 16
(2001)
HER2/neu Analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescent in situ hybridization approach
Ian Ellis, J. Bartlett, Mitchell Dowsett, S. Humphreys, Bharat Jasani, Keith Miller, Sarah Pinder, Anthony Rhodes, Rosemary Walker (2004)
Best Practice No 176Journal of Clinical Pathology, 57
H. Tsuda, F. Akiyama, H. Terasaki, T. Hasegawa, M. Kurosumi, M. Shimadzu, S. Yamamori, G. Sakamoto (2001)
Detection of HER‐2/neu (c‐erb B‐2) DNA amplification in primary breast carcinomaCancer, 92
M. Skacel, Bradley Skilton, J. Pettay, R. Tubbs (2002)
Tissue Microarrays: A Powerful Tool for High-Throughput Analysis of Clinical Specimens: A Review of the Method With Validation DataApplied Immunohistochemistry & Molecular Morphology, 10
P. Lal, Paulo Salazar, C. Hudis, M. Ladanyi, Beiyun Chen (2004)
HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring.American journal of clinical pathology, 121 5
Cheryl Gillett, R. Springall, Diana Barnes, A. Hanby (2000)
Multiple tissue core arrays in histopathology research: a validation studyThe Journal of Pathology, 192
K. Egervari, Z. Szollosi, Z. Nemes, V. Kaczur (2006)
Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice.American journal of clinical pathology, 125 1
R. Cahill, D. Walsh, R. Landers, R. Watson (2006)
Preoperative Profiling of Symptomatic Breast Cancer by Diagnostic Core BiopsyAnnals of Surgical Oncology, 13
K. Egervari, Z. Szollosi, Z. Nemes (2007)
Tissue microarray technology in breast cancer HER2 diagnostics.Pathology, research and practice, 203 3
M. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, D. Cameron, M. Dowsett, C. Barrios, G. Steger, C. Huang, M. Andersson, M. Inbar, M. Lichinitser, I. Láng, U. Nitz, H. Iwata, C. Thomssen, C. Lohrisch, T. Suter, J. Rüschoff, T. Suto, V. Greatorex, C. Ward, C. Straehle, E. McFadden, M. Dolci, R. Gelber (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.The New England journal of medicine, 353 16
M. Owens, B. Horten, M. Silva (2004)
HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues.Clinical breast cancer, 5 1
A. Sapino, C. Marchiò, R. Senetta, I. Castellano, L. Macrì, P. Cassoni, G. Ghisolfi, M. Cerrato, E. D’Ambrosio, G. Bussolati (2006)
Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedureVirchows Archiv, 449
(2005)
Correlation of HER2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas
A. Hidalgo, P. Piña, G. Guerrero, M. Lazos, M. Salcedo (2003)
A simple method for the construction of small format tissue arraysJournal of Clinical Pathology, 56
H. Yamauchi, V. Stearns, D. Hayes (2001)
When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 8
R. Bhargava, P. Lal, Beiyun Chen (2004)
Feasibility of Using Tissue Microarrays for the Assessment of HER-2 Gene Amplification by Fluorescence In Situ Hybridization in Breast CarcinomaDiagnostic Molecular Pathology, 13
S. Taucher, M. Rudas, R. Mader, M. Gnant, P. Dubsky, S. Roka, T. Bachleitner, D. Kandioler, G. Steger, M. Mittlböck, R. Jakesz (2004)
Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancerWiener Klinische Wochenschrift, 116
(2003)
Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybriduzation for HER-2 in 426 breast carcinomas
A. O'Grady, Claire Flahavan, E. Kay, H. Barrett, M. Leader (2003)
HER-2 Analysis in Tissue Microarrays of Archival Human Breast Cancer: Comparison of Immunohistochemistry and Fluorescence In Situ HybridizationApplied Immunohistochemistry & Molecular Morphology, 11
H. Burstein (2005)
The distinctive nature of HER2-positive breast cancers.The New England journal of medicine, 353 16
J. Kononen, L. Bubendorf, Anne Kallionimeni, M. Bärlund, P. Schraml, S. Leighton, J. Torhorst, M. Mihatsch, G. Sauter, Olli-P. Kallionimeni (1998)
Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 4
D. Gancberg, A. Leo, G. Rouas, T. Järvinen, A. Verhest, J. Isola, M. Piccart, D. Larsimont (2002)
Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma.Journal of clinical pathology, 55 4
P. Lal, L. Tan, Beiyun Chen (2005)
Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas.American journal of clinical pathology, 123 4
M. Dowsett, J. Bartlett, I. Ellis, J. Salter, M. Hills, E. Mallon, A. Watters, T. Cooke, C. Paish, P. Wencyk, S. Pinder (2003)
Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER‐2 in 426 breast carcinomas from 37 centresThe Journal of Pathology, 199
E. Romond, E. Perez, J. Bryant, V. Suman, C. Geyer, N. Davidson, E. Tan-chiu, S. Martino, S. Paik, P. Kaufman, S. Swain, T. Pisansky, L. Fehrenbacher, L. Kutteh, V. Vogel, D. Visscher, G. Yothers, R. Jenkins, A. Brown, S. Dakhil, E. Mamounas, W. Lingle, P. Klein, J. Ingle, N. Wolmark (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.The New England journal of medicine, 353 16
H. Yaziji, L. Goldstein, T. Barry, R. Werling, H. Hwang, G. Ellis, J. Gralow, R. Livingston, A. Gown (2004)
HER-2 testing in breast cancer using parallel tissue-based methods.JAMA, 291 16
R. Simon, M. Mirlacher, G. Sauter (2003)
Tissue microarrays in cancer diagnosisExpert Review of Molecular Diagnostics, 3
C. Connor, O. Tawfik, Alina Joyce, Marilyn Davis, M. Mayo, W. Jewell (2002)
A comparison of prognostic tumor markers obtained on image-guided breast biopsies and final surgical specimens.American journal of surgery, 184 4
TECHNICAL ARTICLE Tissue Microarrays for Routine Diagnostic Assessment of HER2 Status in Breast Carcinoma Primozˇ Drev, DVM, MS, Snjezˇana Frkovic´ Grazio, MD, PhD, and Matej Bracˇko, MD, PhD Breast cancers that overexpress HER2 have unfavorable Abstract: The use of tissue microarray (TMA) technology may prognosis and show several distinctive features: they are substantially reduce the costs of routine testing of breast typically poorly differentiated, have a high proliferative carcinomas for human epidermal growth factor receptor 2 rate, often lack hormone receptors, and tend to present at (HER2) status. After a preliminary pilot study comparing the a more advanced stage. TMA results with those obtained on whole section, which Apart from its prognostic role, HER2 status showed an excellent agreement (with kappa values >0.90) for impacts the treatment of breast cancer as it predicts both immunohistochemical and fluorescent in situ hybridization response to certain anticancer therapies. HER2 positivity (FISH) method, we introduced the TMA technique in our is apparently associated with relative resistance to routine work. A total of 1158 invasive breast carcinomas were endocrine therapies. Furthermore, women with HER2- submitted for the determination of HER2 status, which was positive tumors might be relatively resistant to alkylating assessed in 74
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Mar 1, 2008
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.